E. Green

发表

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients

N. Rosenfeld, R. Hastings, J. Stebbing, 2021, Breast Cancer Research and Treatment.

Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.

D. Planchard, C. Caramella, L. Lacroix, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives.

I. Bisson, J. Hyllner, N. Mount, 2015, Regenerative medicine.

Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples

N. Rosenfeld, D. Planchard, V. Plagnol, 2016 .

Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay.

D. Planchard, V. Plagnol, P. Saintigny, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells

M. Plebanski, A. Stephens, A. Rainczuk, 2019, Cancers.

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

C. Lázaro, G. Capellá, D. Planchard, 2020 .

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

J. Blay, D. Planchard, J. Mazières, 2020, Clinical Cancer Research.

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

N. Rosenfeld, S. Johnston, N. Turner, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ctDNA detection by personalised assays in early-stage NSCLC

R. Rintoul, D. Gale, S. Harden, 2021, medRxiv.

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

N. Rosenfeld, Michelle Pugh, John D. Calaway, 2018, PloS one.

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

N. Rosenfeld, D. Planchard, V. Plagnol, 2019, JCO precision oncology.

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

D. Planchard, P. Saintigny, L. Lacroix, 2020, PloS one.

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.

D. Planchard, V. Plagnol, J. Adam, 2020, JCO precision oncology.

Abstract A52: Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI)

R. Govindan, D. Morgensztern, Jennifer C. King, 2020 .

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

D. Planchard, C. Caramella, L. Lacroix, 2020 .

Chemoresistance is mediated by ovarian cancer leader cells in vitro

M. Plebanski, Amy Wilson, A. Stephens, 2021, Journal of experimental & clinical cancer research : CR.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

N. Rosenfeld, D. Planchard, V. Plagnol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer

D. Planchard, J. Mazières, P. Saintigny, 2019, Journal of Thoracic Oncology.

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

D. Planchard, V. Plagnol, J. Adam, 2018 .

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.

C. Lázaro, G. Capellá, D. Planchard, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).

V. Plagnol, J. Soria, L. Lacroix, 2017 .

Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study.

B. Yaremko, G. Rodrigues, D. Palma, 2020 .

Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

P. Saintigny, D. Pérol, K. Howarth, 2018 .